Therapies in the pipeline
THERAPIES IN THE PIPELINE
1. Geron (GERN) Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers.
http://www.cbsnews.com/video/watch/?id=1346482n&tag=api”>Video
STATUS : FDA APPROVED TRIALS FOR ACUTE SPINAL CORD INJURY IN PROGRESS (Embryonic Stem Cells)
2.TCA Cellular Therapy, LLC (TCA-CT) is a privately-held biotherapeutics company whose mission is to create and accelerate adult stem cell therapies and to develop next generation treatments for serious and life-threatening diseases. The company utilizes single or a combination of autologous (patient’s own) adult stem cells to treat various diseases, related to the cardiovascular, nervous, skeletal and muscular systems. Six FDA-approved clinical trials at Phases I, II and/or II/III are underway to treat Heart Disease, Peripheral Vascular Disease (PVD), Peripheral Arterial Disease (PAD), Limb Ischemia, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) and Spinal Cord Injuries. http://www.tcacellulartherapy.com/
STATUS : FDA APPROVED TRIALS FOR CHRONIC SPINAL CORD INJURY IN PROGRESS (Bone Marrow Stem Cells)
3. Neuralstem, Inc. (CUR) Neuralstem, Inc. is a biotherapeutics company utilizing its patented Human Neural Stem Cell technology to create cures for diseases of the CNS (central nervous system). The Company’s technology allows for the isolation of CNS stem cells from tissue; the expansion in vitro of each cell up to a billion billion times (60 doublings), and the controlled differentiation of the cells into mature, physiologically relevant human neurons and glia.
STATUS : WAITING FOR FDA APPROVAL TRIALS FOR CHRONIC SPINAL CORD INJURY (Neural Stem Cells)
4. Spinal Cord Injury Network USA (SCINetUSA) Established In March 2009 in Austin, Texas, Dr. Wise Young announced the launching of the Spinal Cord Injury Network USA (SCINetUSA) to test treatments for chronic spinal cord injury. The network is responsible for the organization, administration, training, development of protocols, and government approvals of the clinical trial. Participating centers select participants and conduct the trials. SCINetUSA has been working to develop consensus for the clinical trials in a series of meetings in China and New Jersey.
These are among the first clinical trials for people with chronic injuries. Projected to start in 2011, the trials will use umbilical cord blood and a drug called lithium in combination with rigorous physical therapy. The creation of SCINetUSA means that U.S. citizens will not have to travel overseas to participate in clinical trials.
STATUS : WAITING FOR FDA APPROVAL- TRIALS FOR CHRONIC SPINAL CORD INJURY IN PROGRESS IN CHINA (Umbilical Cord Stem Cells)
5. Invivo Therapeutics Corp. The mission of InVivo Therapeutics is to provide society with superior neurological products and services by delivering novel approaches to the treatment of disease that will improve the quality of life and satisfy the needs of those who live with spinal cord injury. We also seek to empower our employees to create new treatment options for spinal cord injuries with the expectation that they will have the opportunity to make a difference in the lives of all people impacted by these injuries.
STATUS : WAITING FOR FDA APPROVAL- TRIALS FOR ACUTE SPINAL CORD INJURY (Polymer Scaffolding)
